Inhibition of asparagine synthetase effectively retards polycystic kidney disease progression

Abstract Polycystic kidney disease (PKD) is a genetic disorder characterized by bilateral cyst formation. We showed that PKD cells and kidneys display metabolic alterations, including the Warburg effect and glutaminolysis, sustained in vitro by the enzyme asparagine synthetase (ASNS). Here, we used...

Full description

Bibliographic Details
Published in:	EMBO Molecular Medicine
Main Authors:	Sara Clerici, Christine Podrini, Davide Stefanoni, Gianfranco Distefano, Laura Cassina, Maria Elena Steidl, Laura Tronci, Tamara Canu, Marco Chiaravalli, Daniel Spies, Thomas A Bell, Ana SH Costa, Antonio Esposito, Angelo D’Alessandro, Christian Frezza, Angela Bachi, Alessandra Boletta
Format:	Article
Language:	English
Published:	Springer Nature 2024-04-01
Subjects:	ADPKD Glutamine Metabolism Metabolic Reprogramming Antisense Oligonucleotides Glycolysis
Online Access:	https://doi.org/10.1038/s44321-024-00071-9

Similar Items

Asparagine synthetase modulates glutaminase inhibitor sensitivity through metabolic reprogramming and serves as a prognostic biomarker in hepatocellular carcinoma
by: Benjian Gao, et al.
Published: (2025-10-01)

Changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to <i>apoB</i>, <i>PCSK9</i>, and <i>apoCIII</i> mRNAs
by: S. I. Oshevski, et al.
Published: (2020-01-01)

The efficacy of simultaneous action of several antisense oligonucleotide derivatives by the example of lipid metabolism in mice
by: S. I. Oshevskii, et al.
Published: (2015-09-01)

LIPID METABOLISM CORRECTION BY ANTISENSE TECHNOLOGY
by: O. I. Afanasieva, et al.
Published: (2015-09-01)

Asparagine Synthetase in Cancer: Beyond Acute Lymphoblastic Leukemia
by: Martina Chiu, et al.
Published: (2020-01-01)

Metabolism of Tryptophan, Glutamine, and Asparagine in Cancer Immunotherapy—Synergism or Mechanism of Resistance?
by: Kajetan Kiełbowski, et al.
Published: (2025-02-01)

Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys
by: Colby S Shemesh, et al.
Published: (2016-01-01)

Inhibitory Effect of Nano-oligonucleotides as a New Nanotechnology Method in Gene Therapy of Leukemia In Vitro
by: N Naghsh, et al.
Published: (2011-06-01)

Inhibitory Effect of Nano-oligonucleotides as a New Nanotechnology Method in Gene Therapy of Leukemia In Vitro
by: Rabbani M, et al.
Published: (2011-06-01)

The use of 31P NMR and principal components analysis to determine sameness or differences between diastereomeric composition of phosphorothioate oligonucleotides
by: Luca Gherardi, et al.
Published: (2026-08-01)

Novel insights into regulation of asparagine synthetase in conifers
by: Javier eCanales, et al.
Published: (2012-05-01)

Can GLP-1 receptor agonists slow the progression of Autosomal Dominant Polycystic Kidney Disease?
by: Hamad Ali, et al.
Published: (2025-06-01)

Bone health in autosomal dominant polycystic kidney disease (ADPKD) patients after kidney transplantation
by: Dalia Zubidat, et al.
Published: (2023-06-01)

Therapeutic Potential of STE20-Type Kinase STK25 Inhibition for the Prevention and Treatment of Metabolically Induced Hepatocellular CarcinomaSummary
by: Ying Xia, et al.
Published: (2025-01-01)

Antisense Therapy for Infectious Diseases
by: Lwanda Abonga Buthelezi, et al.
Published: (2023-08-01)

Lipid and Peptide-Oligonucleotide Conjugates for Therapeutic Purposes: From Simple Hybrids to Complex Multifunctional Assemblies
by: Carme Fàbrega, et al.
Published: (2023-01-01)

Characterizing asparagine synthetase deficiency variants in lymphoblastoid cell lines
by: Stephen J. Staklinski, et al.
Published: (2023-03-01)

THERAPEUTIC ANTISENSE OLIGONUCLEOTIDES AGAINST CANCER: HURDLING TO THE CLINIC
by: Pedro Miguel Duarte Moreno, et al.
Published: (2014-10-01)

Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
by: Rosie Z Yu, et al.
Published: (2016-01-01)

In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney
by: Toshiki Tsuboi, et al.
Published: (2025-03-01)

Transport Oligonucleotides—A Novel System for Intracellular Delivery of Antisense Therapeutics
by: Oleg V. Markov, et al.
Published: (2020-08-01)

Asparagine, a critical limiting metabolite during glutamine starvation
by: Jie Jiang, et al.
Published: (2018-05-01)

The RNA revolution in medicine: from gene regulation to clinical therapeutics
by: Jiwon Jeong, et al.
Published: (2025-12-01)

Chemistry of Therapeutic Oligonucleotides That Drives Interactions with Biomolecules
by: Chisato Terada, et al.
Published: (2022-11-01)

Downregulation of Glutamine Synthetase, not glutaminolysis, is responsible for glutamine addiction in Notch1‐driven acute lymphoblastic leukemia
by: Tra Ly Nguyen, et al.
Published: (2021-05-01)

Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis
by: Erika M. Palmieri, et al.
Published: (2017-08-01)

Genome-wide identification and expression analysis of asparagine synthetase family in apple
by: Xi-sen YUAN, et al.
Published: (2020-05-01)

Minireview on Glutamine Synthetase Deficiency, an Ultra-Rare Inborn Error of Amino Acid Biosynthesis
by: Marta Spodenkiewicz, et al.
Published: (2016-10-01)

Locked nucleic acid-modified antisense oligonucleotides attenuate scar hyperplasia through targeted inhibition of CTGF
by: Jinhe Li, et al.
Published: (2025-08-01)

Antisense oligonucleotides for the arterial hypertension mechanisms study and therapy
by: L. O. Klimov, et al.
Published: (2018-04-01)

Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer
by: Guillaume Sicard, et al.
Published: (2020-11-01)

Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma
by: Alexandre Khuu, et al.
Published: (2024-11-01)

Delivery of Oligonucleotides Using a Self-Degradable Lipid-Like Material
by: Hiroki Tanaka, et al.
Published: (2021-04-01)

Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies
by: Craig S. McIntosh, et al.
Published: (2021-10-01)

Rheumatoid Arthritis Has Won the Battle but Not the War: How Many Joints Will We Save Tomorrow?
by: Volodymyr V. Oberemok, et al.
Published: (2023-10-01)

INHIBITION OF THE EXPRESSION OF PHYSIOLOGICAL PRIONS WITH ANTISENS-OLIGONUCLEOTIDES
by: N. U. Susol, et al.
Published: (2017-10-01)

In-silico study of antisense oligonucleotide antibiotics
by: Erica S. Chen, et al.
Published: (2023-11-01)

miRNA displacement as a promising approach for cancer therapy
by: David Gilot, et al.
Published: (2018-01-01)

Traducción independiente de la estructura 5´cap del ARN genómico del virus dengue
by: Mariela Pérez Dominguez, et al.

Therapeutic Lowering of C-Reactive Protein
by: Rachel V. Jimenez, et al.
Published: (2021-01-01)